GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (STU:9RP) » Definitions » Profitability Rank

Lipigon Pharmaceuticals AB (STU:9RP) Profitability Rank : 0 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lipigon Pharmaceuticals AB Profitability Rank?

Lipigon Pharmaceuticals AB has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Lipigon Pharmaceuticals AB's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, Lipigon Pharmaceuticals AB's Piotroski F-Score is 9999.


Competitive Comparison of Lipigon Pharmaceuticals AB's Profitability Rank

For the Biotechnology subindustry, Lipigon Pharmaceuticals AB's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipigon Pharmaceuticals AB's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipigon Pharmaceuticals AB's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Lipigon Pharmaceuticals AB's Profitability Rank falls into.



Lipigon Pharmaceuticals AB Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Lipigon Pharmaceuticals AB has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Lipigon Pharmaceuticals AB's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-0.655 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Lipigon Pharmaceuticals AB has an F-score of 9999. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Lipigon Pharmaceuticals AB Profitability Rank Related Terms

Thank you for viewing the detailed overview of Lipigon Pharmaceuticals AB's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipigon Pharmaceuticals AB (STU:9RP) Business Description

Traded in Other Exchanges
Address
Tvistevagen 48 C, Umea, SWE, 90736
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.

Lipigon Pharmaceuticals AB (STU:9RP) Headlines

No Headlines